This is a single-blind randomized controlled trial, aiming to evaluate the effects of vaginal seeding on body mass index as well as allergy risk for cesarean-delivered infants. It will be conducted in Liuyang city of China, and the targeted sample size is 106. All the eligible pregnant women will be randomly assigned to either the intervention or control group, and their babies of the participants will be followed up to 24 months of age.
Many studies have suggested that caesarean-delivered children are at higher risks of developing metabolic and allergic diseases like obesity and asthma, possibly because newborns born by caesarean section were lack of exposure to maternal vaginal flora. It is needed to explore a simple, convenient, and safe intervention strategy to reduce caesarean-related risks. In a recent non-randomized study, the authors found that exposure of caesarean-delivered newborns to maternal vaginal fluid at birth (i.e., vaginal seeding) could partially restore the microbiota of them at 30 days after births, but the long-term health consequences of restoring the microbiota of caesarean-delivered infants remain unclear. In this randomized study, the investigators aim to examine whether the changes in newborns' microbiota will persist to 24 month of age, and whether vaginal seeding will have any effects on body mass index and allergy risk from birth to 24 months of age. the investigators will enroll a total of 106 pregnant women, and the participants' infants will be followed up at 0 (before hospital discharge), 6, 12, 18 and 24 months. At each follow-up visit, a questionnaire survey including information on feeding, medication, and allergic status will be conducted, infants' height and weight will be measured, and feces will be collected. At 18-month-old visit, infants' venous blood will be also collected for the assay of multiallergen. The primary outcomes were body mass index and allergy risk index. The secondary outcomes included the microbiota profile, allergic symptoms and diseases, overweight/obesity, and adverse effects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
117
The same as that stated in arm descriptions.
Liuyang Maternal and Child Health Care Hospital
Guankou, Hunan, China
infant's body mass index
Body mass index in original scale and z-score
Time frame: At 6 months
infant's body mass index
Body mass index in original scale and z-score
Time frame: At 12 months
infant's body mass index
Body mass index in original scale and z-score
Time frame: At 18 months
infant's body mass index
Body mass index in original scale and z-score
Time frame: At 24 months
infant's allergy risk score
Calculated based on the measurements of multiallergens with 0-6 classes,higher values represent a worse outcome which means more susceptible to allergic diseases
Time frame: At 18 months after birth
Infants' gut microbiota profile
Intestinal flora will be detected by 16sRNA sequencing using feces samples
Time frame: At baseline (Meconium), 6, 12 ,18 and 24 months after birth
Rate of overweight/obesity
Defined by body mass index
Time frame: At 6, 12 ,18 and 24months
Rate of allergic symptoms and common allergic diseases
Collected by using a structured questionnaire
Time frame: At 61, 12 ,18 and 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rate of adverse effects
Infection-related diseases and others
Time frame: From birth to 24 months